Clinical trials
Alzheimer's Disease Dementia clinical trials
Below are recruiting alzheimer's disease dementia clinical trials, each written for real people, not researchers. We’re tracking 462 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06833645Recruiting
PET scans to spot early Alzheimer's changes
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
Chengdu, SichuanAges 18 years+ - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07251023RecruitingPhase 3
Testing a new drug for Alzheimer's dementia
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
Kazan'Ages 60–90 - NCT07496021Recruiting
Probiotic for early Alzheimer's: safety and memory benefits
This trial tests a new probiotic (Lactococcus lactis CKDB001) to see if it can slow memory loss in people with early Alzheimer's. It’s a 12-week study that requires a positive amyloid PET scan and allows mild to moderate symptoms.
Gyeonggi-doAges 55–85 - NCT07599670RecruitingPhase 1/Phase 2
Safety study of ABBV-1758 injection for Alzheimer's disease
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Irvine, CaliforniaAges 50–90 - NCT06451952Recruiting
Virtual darkness therapy for agitation in dementia
This trial tests whether virtual darkness therapy (sitting in a dim, calming environment) can reduce agitation in people with dementia. It is designed for patients at NKS Olaviken hospital who have significant agitation.
Askøy, ErdalAges 50 years+ - NCT05643144Recruiting
Shared decisions for dementia and diabetes care
This study tests a program that helps people with both memory problems (like dementia or mild cognitive impairment) and diabetes, along with their caregivers, make better care decisions together. It uses a special device to track blood sugar without fingersticks.
Indianapolis, IndianaAges 65 years+ - NCT03657745Recruiting
40 Hz light and brain training for Alzheimer’s
This trial tests whether a combination of 40 Hz light stimulation and cognitive (thinking) therapy can improve symptoms in people with Alzheimer’s disease. It may help by stimulating the brain and training thinking skills, while carefully checking eye and seizure history.
Miami, FloridaAges 50 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT06875739Enrolling by invitation
Saliva test for early diagnosis of brain diseases
This study tests whether a saliva sample can help tell the difference between brain diseases like Alzheimer's, Parkinson's, and related conditions. By using a special laser technique, researchers hope to find a quick, non-invasive way to make an earlier and more accurate diagnosis.
CagliariAges 60–85 - NCT07409506Recruiting
How caregivers help people with Alzheimer's
This study looks at the support that caregivers provide to people with Alzheimer's disease at different stages. It helps researchers understand how caregiving changes over time, which can lead to better support for both patients and their families.
VilleurbanneAges 60 years+ - NCT03890861Recruiting
Exercise program to help lower Alzheimer’s risk
This trial studies whether a structured group exercise program can help lower Alzheimer’s disease risk in older African Americans. You would be assigned to a group by chance and asked to attend regular sessions if it’s safe for you to exercise.
Baton Rouge, LouisianaAges 60 years+ - NCT07482800Recruiting
Dementia in stories and real-life medical cases
This study looks at how people with early Alzheimer's or mild memory problems understand stories compared to healthy adults. Your participation could help researchers learn more about how dementia affects thinking and language.
New Taipei CityAges 60–85 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT05020626Recruiting
Uses brain MRI data to study Alzheimer’s disease diagnosis
This study uses brain MRI images to better understand how a protein called tau spreads in Alzheimer’s disease and related conditions. If you’re 55 or older and had an MRI close to your diagnosis, you may be eligible.
Hong Kong, ShatinAges 55 years+ - NCT07059871Recruiting
Silkworm powder for nutrition in Alzheimer's disease
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
Hangzhou, ZhejiangAges 50–90 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Scottsdale, ArizonaAges 55–90 - NCT05995418Recruiting
Cost and health impact study for Alzheimer's in China
This study looks at the financial and health effects of Alzheimer's disease and mild cognitive impairment (aMCI) in China. It aims to understand how the disease affects patients and families over time.
BeijingAges 40–100 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease dementia?
- Yes. Clin2 currently lists 462 recruiting alzheimer's disease dementia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease dementia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease dementia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.